Meeting
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
Authors
Paul Lorigan
Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Paul Lorigan , Theresa Medina , Marta Nyakas , Annemie Rutten , Lynn G. Feun , Charles Lance Cowey , Miranda Payne , Israr Hussain , Timothy Kuzel , Steven O'Day , Amna Sheri , Philip Adam Friedlander , Satish Kumar , Jens Bjorheim , Oliver Edgar Bechter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04382664
Citation
J Clin Oncol 42, 2024 (suppl 17; abstr LBA9519)
DOI
10.1200/JCO.2024.42.17_suppl.LBA9519
Abstract #
LBA9519
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
First Author: Georgina V. Long
Poster
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
First Author: Claire Frances Friedman
Poster
2016 ASCO Annual Meeting
Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.
First Author: Simon B. Zeichner